What can we learn about schizophrenia from studying the human model, drug‐induced psychosis?

  title={What can we learn about schizophrenia from studying the human model, drug‐induced psychosis?},
  author={Robin M. Murray and Alessandra Paparelli and Paul D. Morrison and Arianna Marconi and Marta di Forti},
  journal={American Journal of Medical Genetics Part B: Neuropsychiatric Genetics},
  pages={661 - 670}
  • R. MurrayA. Paparelli M. di Forti
  • Published 1 October 2013
  • Psychology, Medicine
  • American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
When drug‐induced psychoses were first identified in the mid‐20th century, schizophrenia was considered a discrete disease with a likely genetic cause. Consequently, drug‐induced psychoses were not considered central to understanding schizophrenia as they were thought to be phenocopies rather than examples of the illness secondary to a particular known cause. However, now that we know that schizophrenia is a clinical syndrome with multiple component causes, then it is clear that the drug… 

Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis

Several DIP models such as of amphetamine, PCP/ketamine, scopolamine, and LSD are covered, and three schizophrenia models are addressed through a genetic approach with a new perspective that distinguishes DIP from schizophrenia.

Psychosis in Parkinson’s disease and parkinsonism in antipsychotic-naive schizophrenia spectrum psychosis: clinical, nosological and pathobiological challenges

It is proposed that time- and site-dependent dysfunction in such a neuronal network may be a generic substrate for the emergence of psychosis not only in Parkinson’s disease and schizophrenia-spectrum disorders but also in other neuropsychiatric disorders in which psychosis, and sometimes movement disorders, can be encountered.

The Immune and Metabolic Factors of Schizophrenia

This review discusses how metabolic and immune dysfunction may help explain and unify the genetic and environmental hypothesis of schizophrenia, and discusses how aberrant release of inflammatory markers from immune cells, adipocytes and glial cells could contribute to schizophrenia.

Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles

A better understanding of these compounds might improve knowledge of the processes involved in consciousness, the neuropathology of depression, and potentially open up new pharmacological therapies, as well as improve safety and clinical application.

Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation

It is shown that drug effects on the P20–N40 are highly predictive of human effects across similar dose ranges and hypothesized neuropharmacologic mechanisms that may underlie gating effects for each drug studied are discussed.

Cannabis points to the synaptic pathology of mental disorders: how aberrant synaptic components disrupt the highest psychological functions

Many of the most robust findings in psychiatric genetics include components that localize to dendritic spines and have important roles in information processing and plasticity.

Substance-induced psychosis and schizophrenia: the interaction point

Current data and discussion on the similarities and differences between induced psychosis and schizophrenia are provided and the possibility of differentiation at the clinical level and main difficulties in clear diagnostic are discussed.

Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol - A mega analysis of individual participant-data from human laboratory studies.

Intravenous administration of THC consistently induces psychotomimetic effects that include symptoms across PANSS domains, and healthy subjects who frequently use cannabis, have a blunted psychotomIMetic response.



What causes the onset of psychosis?

Recent advances in the phencyclidine model of schizophrenia.

It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP and the findings suggest that endogenous dysfunction of NMDA receptor-mediated neurotransmission might contribute to the pathogenesis of schizophrenia.

Study of a new schizophrenomimetic drug; sernyl.

Introduction The production of model psychoses has been employed as a technique for testing hypotheses relevant to the causes, correlates, and treatment of schizophrenia since 1921, when De Jong

Schizophrenia: From developmental deviance to dopamine dysregulation

Provocative tests with psychostimulant drugs in schizophrenia

The results suggest the presence of a subgroup of schizophrenic patients who exhibit psychotic symptom activation with PS in a state dependent or independent fashion and this biologic phenomenon may be clinically exploitable and should be investigated further.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

The data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia.

LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry.

  • M. VardyS. Kay
  • Psychology, Medicine
    Archives of general psychiatry
  • 1983
A model of LSD psychosis as a drug-induced schizophreniform reaction in persons vulnerable to both substance abuse and psychosis is supported, supported by the findings of whether patients hospitalized for LSD psychosis are clinically separable from acute schizophrenia.

Dopaminergic sensitization: Implications for the pathogenesis of schizophrenia

Psychological effects of ketamine in healthy volunteers

Ketamine does not reproduce the full picture of schizophrenia, but Phenomena resembling negative symptoms are seen, but the distinction of these from the drug's sedative effects requires further elucidation.

Phenotype of schizophrenia: a review and formulation

The status of general knowledge in this area is reviewed and an approach to discovery is proposed, including identifying brain regions of dysfunction and subsequent localized, hypothesis-driven molecular screening.